Online Medical Misinformation in Cancer: Distinguishing Fact From Fiction [Mar 31, 2022] @drteplinsky et al. @JCOOP_ASCO https://t.co/wTBVD2670C #Scicomm #COSMonc @COSMOCollab

Hormonal Contraceptive Formulations and Breast Cancer Risk by F. Hadizadeh et al @JAMAOnc: - Data for roughly 2M women analyzed - Hormonal contraceptives linked to ⬆️ breast cancer risk - Progestin-only desogestrel w/ ⬆️ risk vs levonorgestrel #OncTwitter #bcsm @OncoAlert

Thrilled to have another non hormonal option with elinzanetant for our patients - especially those not candidates for MHT or choose not to take it! #bcsm #menopause @AgrawalNina⁩

Such a great conversation about the value of podcasts in medical and patient education!! Thanks for having me! @JCOOP_ASCO!

DB05 T-DXd vs TDM1 in pts w/HER2+ RCB after neoadj. cT2N0 excded, concurrent ☢️ ok CT high res Q12 wks after baseline 8.7% ⬆️ in IDFS (HR 0.47) Immature OS, DRFS, brain met free survival, but favorable trend ❓W/shifting data for oral combos, is duration & AEs acceptable? #ESMO25

Excellent question from the audience. Why in the world are we still using single agent fulvestrant control arms in 2025? Apparently @US_FDA mandated this in Viktoria 1.

Although giredestrant + everolimus showed improved PFS in both mutESR1 and ITT (wt and mutESR1), an exploratory analysis suggests that the mutESR1 population is driving the benefit in the ITT group, with no difference in PFS for the wt subgroup analysis. #ESMO25 @OncoAlert

VIKTORIA-1: Gedatolisib + fulvestrant ± palbociclib vs fulvestrant in pts with HR+/ HER2-/PIK3CA WT MBC: mPFS 9.3 mo in triplet, 7.4 mo in doublet, 2 mo in fulvestrant alone. @myESMO #ESMO25

#ESMO25 - Patients with metastatic breast cancer who had received ≥ 2 years of bone modifying agents🦴were randomized to continue standard dosing (Q4W) or de-escalate to Q24W De-escalation preserved physical function without increasing skeletal events @OncoAlert

Great article and puts everything into perspective! #ESMO25 @myESMO

At #ESMO25 we’ll see mature data on CDK4/6 inhibitors. We are using these drugs more & more in our 🏥! With @DrSGraff in #ToxCheck 🗣️ we reviewed Palbo, Ribo & Abema AEs + management Full 🗣️ ⭐️ https://t.co/3971MEBzwm ⭐️ “Oncology Brothers” podcast #OncTwitter @OncUpdates

It is a new era for ADCs in ovarian cancer (and gynecologic cancer in general). #gyncsm #ESMO25

Interesting to see development of novel FRalpha - ADCs! #ovariancancer #ESMO25 #gyncsm

An important point that PARP exposure is not the same as PARP resistance in ovarian cancer and some patients may benefit from PARP inhibitor rechallenge. #gyncsm #ESMO25

NATALEE Adj Ribo shows sustained improvement in IDFS. Hot take (the dreaded cross trial comparison): NATALEE is a lower risk population, so that long slow follow-up is critical with 50% of HR+ recurrences happening >5 years, and that OS trend is promising. #ESMO24 @OncoAlert

Great discussion by @AngieDemichele reviewing the updated NATALEE and MonarchE data and next steps. #ESMO25

Are you seeking ways to improve the address best practices in shared decision-making & high-quality treatment of advanced breast cancer? Join the @AmericanCancer for an ECHO program on Improving Treatment of Advanced Breast Cancer. #bcsm Register: https://t.co/mvhecePx5r

Exploring Berlin before #ESMO25!

Happy to share press release from this morning that #HER2CLIMB05 is positive - tucatinib in 1L HER-2+ maintenance improves PFS. Options expanding in this space! #bcsm https://t.co/OQU6TukmKg

Not too late to register for this free online educational event for patients and caregivers ..!